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Abstract
Background and purpose: Ongoing evaluation of the results
of thrombolytic therapy in patients with ischaemic stroke (IS)
in regions with different health care organization is absolute-
ly crucial for making this method of treatment safer and effi-
cient. The aim of this study was to analyse the efficacy and
safety of treatment with intravenous alteplase in patients with
acute IS in a rural hospital.
Material and methods: Between 2006 and 2011, 1392 pa -
tients with IS were treated (including 200 patients treated
with alteplase; 14.37%). In patients treated with alteplase, we
analysed the influence of several variables on the functional
status after 3 months according to the modified Rankin Scale
(mRS), case-fatality rate during 3 months after onset and
symptomatic intracerebral haemorrhage (SICH).
Results: In the studied population, good outcome (mRS 
0-2) at 3 months was related to younger age (p = 0.001), male
sex (p = 0.02) and low scores (< 15 points) on the National
Institutes of Health Stroke Scale (NIHSS) (p < 0.0001).
Deaths within 3 months were related to older age (p = 0.027),
female sex (p = 0.004), severity of stroke measured by NIHSS
score (p < 0.0001) and presence of radiological signs of pre-
vious stroke in baseline computed tomography (CT) 
(p = 0.002). Patients with SICH had higher mean age 
(p = 0.014) and higher severity of neurological deficit mea-
sured on the NIHSS scale (p = 0.03).
The efficacy and safety of intravenous thrombolysis with alteplase 
in the treatment of ischaemic stroke in a rural hospital
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St reszc zen ie
Wstêp i cel pracy: Prowadzenie ci¹g³ej oceny wyników le cze -
nia trombolitycznego chorych na udar niedokrwienny mózgu
(UNM) w regionach ró¿ni¹cych siê organizacj¹ ochrony zdro-
wia ma du¿e znaczenie dla skuteczniejszego oraz bezpiecz -
niejszego stosowania tej metody. Celem pracy by³a analiza sku-
tecznoœci i bezpieczeñstwa leczenia podawan¹ do¿ylnie
alteplaz¹ u chorych na UNM w szpitalu w regionie rolniczym.
Materia³ i metody: W latach 2006–2011 autorzy leczyli 1392
chorych na UNM – alteplazê otrzyma³o 200 pacjentów
(14,37%). W grupie chorych leczonych alteplaz¹ przeanali-
zowano wp³yw wielu czynników na stan funkcjonalny po 
3 miesi¹cach, uwzglêdniaj¹c punktacjê w zmodyfikowanej
skali Rankina (mRS), czêstoœæ zgonów w ci¹gu 3 miesiêcy
od zachorowania oraz czêstoœæ objawowych krwotoków œród-
mózgowych (SICH).
Wyniki: W badanej populacji dobry wynik leczenia (mRS 
0-2) po 3 miesi¹cach wi¹za³ siê z m³odszym wiekiem chorych
(p = 0,001), p³ci¹ mêsk¹ (p = 0,02) i ma³¹ (< 15 pkt) punk-
tacj¹ w Skali Udarowej Narodowych Instytutów Zdrowia
(NIHSS) (p < 0,0001). Zgony w ci¹gu 3 miesiêcy by³y is-
totnie czêstsze wœród osób starszych (p = 0,027), kobiet 
(p = 0,004), osób z du¿ym nasileniem ubytkowych objawów
neurologicznych w skali NIHSS (p < 0,0001) i u osób z obja-
wami przebytego udaru w wyjœciowej tomografii komputero-
wej (TK) (p = 0,002). Grupa chorych z SICH cechowa³a siê
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Introduction
Stroke is the third leading cause of death in the Unit-
ed States, Canada, Europe and Japan. The American
Heart Association and American Stroke Association esti-
mate that approximately 800 000 new strokes occur each
year, resulting in more than 130 000 annual deaths in the
United States alone [1]. The incidence of stroke in Po -
land is similar to that in other European countries (the
incidence rate is 177/100 000 in males and 125/100 000
in females). Half of these patients die within one year,
while the remaining one-half have permanent conse-
quences within the central nervous system [2,3]. Accord-
ing to the Ministry of Health, about 88 500 hospitaliza-
tions with a diagnosis of stroke were reported in 2007 in
Poland (data may be underestimated by about 15%) [4].
Ischaemic stroke (IS) is not a single disease but
a heterogeneous condition with several very different
pathophysiological mechanisms. Identification of the
underlying cause is important for selecting patients for
some specific therapies. One of the most significant ad -
vances during the last two decades has been the intro-
duction of intravenous thrombolysis as a standard ther-
apy for the well-selected population of patients with acute
IS. Intravenous recombinant tissue plasminogen acti-
vator (rt-PA, alteplase) was approved by the Food and
Drug Administration (FDA) based on the results of the
National Institute of Neurological Disorders and Stroke
(NINDS) trial in 1996 in the United States and later
in Canada, Japan, countries of South America and Aus-
tralia [5]. The temporary European license was granted
in 2003 and a European registry of all thrombolysis pro-
cedures, Safe Implementation of Thrombolysis in Stroke
– Monitoring Study (SITS-MOST), was created at the
same time [6]. In 2003, under the same condition as in
other European countries, alteplase temporary approval
was granted [7]. The benefits of intravenous throm-
bolysis are therefore greatest when treatment is initiated
early following stroke onset [8]. Until 2008, an upper
limit of 3 hours for routine use of alteplase in a dose of
0.9 mg/kg after IS was recommended. The third ECASS
(European Cooperative Acute Stroke Study) trial found
that intravenous alteplase administered between 3 and
4.5 hours after the onset of symptoms significantly
improved clinical outcomes in patients with acute IS
[9]. The SITS register has shown that treatment at an
average of 3 hours 15 mi nutes and until 4.5 hours after
stroke onset remains as safe as earlier treatment in rou-
tine clinical practice [10]. In Poland, the drug has been
officially approved for use in a time window of up to 
4.5 hours since September 2010 [11,12].
The aim of this study was to analyse the safety and
efficacy of intravenous thrombolysis in a group of pa tients
with acute IS. All patients treated in the Stroke Unit
Department of Neurology Hospital in Sandomierz were
reported to the SITS registry according to the protocol.
The retrospective evaluation of efficacy and safety of
treatment of patients with a given method may allow the
selection of a group of patients in whom this method will
be of greatest benefit.
Material and methods
The stroke unit in the hospital in Sandomierz takes
care of a 200 thousand population and cooperates in 
this field with five neighbouring hospitals. Two of them
have neurological departments, but without stroke units. 
Fifty percent of our patients were recruited for the treat-
ment with thrombolytic therapy from areas of neighbour -
ing hospitals. Our centre was recognized as a stroke unit
ac cording to the Polish national criteria and equipped
with proper monitoring and diagnostic facilities [13].
We ana lysed the neurological status of the patients at the
mo ment of admission and 3 months after symptoms
onset according to the National Institutes of Health
Stroke Scale (NIHSS) [14] and functional outcome at
3 months after symptoms onset according to the modi-
fied Rankin Scale (mRS) [15]. All patients had com-
Conclusions: The indications for intravenous thrombolysis
in patients with IS should be strictly analysed so that the treat-
ment is effective and safe especially in older patients, patients
with greater severity of neurological symptoms and patients
with old post-stroke lesions in baseline CT. 
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wiêksz¹ œredni¹ wieku (p = 0,014) i wiêkszym nasileniem obja-
wów neurologicznych mierzonych skal¹ NIHSS (p = 0,03). 
Wnioski: Nale¿y œciœle analizowaæ wskazania do do¿ylnej
trombolizy u chorych na UNM, aby leczenie by³o skuteczne
i bezpieczne, w szczególnoœci u chorych starszych, chorych ze
znacznym nasileniem objawów neurologicznych i chorych
z obecnoœci¹ starych ognisk poudarowych w wyjœciowej TK. 
S³owa kluczowe: udar niedokrwienny mózgu, leczenie alte-
plaz¹, region rolniczy.
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puted tomography (CT) of the brain performed: prior
to treatment, 22-36 hours after the start of treatment and
at the seventh day. The patients had additional CT in the
case of neurological deterioration rated as ≥ 4 points on
the NIHSS. 
Early signs of infarction were interpreted according
to von Kummer et al. [16]. Cerebral oedema was clas-
sified according to the SITS Monitoring Study (SITS-
MOST) Final Study Protocol [17]. We used the ECASS
protocol definition of symptomatic intracerebral haem-
orrhage (SICH) [18].
We analysed the impact of various factors on the effi-
cacy and safety of treatment with alteplase. We compared
groups of patients with good (mRS 0-2) and poor (mRS
3-6) outcome, groups of patients who died within 
3 months after stroke onset and survivors, as well as
groups of patients with or without SICH.
The ethics committee approved of our approach to
ascertain and analyse data of all alteplase-treated stroke
patients.
Statistical methods
Statistical analysis was done with Statistica 6.0. Uni-
variate analyses were performed and χ2 tests with appro-
priate corrections (Yates correction, maximum-likeli-
hood χ2 Fisher exact test) for sample size and expected
counts and nonparametric Mann-Whitney U-test were
used. The level of significance was set at p < 0.05. Addi-
tionally, odds ratios (OR) with 95% confidence inter-
vals (CI) were estimated.
Results
Between September 2006 and March 2011, 1392 pa -
tients with acute IS were treated in the stroke unit in San-
domierz, including 200 Caucasian patients (aged 41-92,
mean 69.07 ± 10.57) treated with rt-PA (14.37%).
Demographic data, clinical data including risk factors,
baseline NIHSS score, logistic times, and type of stroke
according to the Oxfordshire Community Stroke Pro-
ject Classification (OCSP) are given in Table 1.
There were more patients with heart disease, espe-
cially with atrial fibrillation, in our study population.
Radiological signs of an old and current stroke in
baseline CT and the incidence of haemorrhagic trans-
formation, SICH and cerebral oedema in control CT
are shown in Table 2.
Baseline CT was normal in 36% of patients; it
revealed signs of previous stroke in 36.5%, and signs of
current stroke in 27.5% of patients. Control CT showed
haemorrhagic transformation in 17.5% of patients,
SICH in 5% and cerebral oedema in 32%.
After 3 months, we found a good outcome (mRS 
0-2) in 58.0% and poor outcome (mRS 3-6) in 42.0%
of patients; 16% of patients died.
Relationships between risk factors, the status of
patients on admission according to NIHSS, radiologi-
Variable*
Sex
Women 88 (44%)
Men 112 (56%)
Age [years]; mean ± SD (range) 69.1 ± 10.6 (41-92)
rt-PA dose [mg]; mean ± SD 64.2 ± 12.8
Onset-to-needle time [min]; 150.5 ± 41.2 (45-270)
mean ± SD (range)
Door-to-needle time [min]; 63.7 ± 28.8 (10-190)
mean ± SD (range)
Baseline NIHSS score; 12.3 ± 5.0
mean ± SD
0-7 43 (21.5%)
8-14 90 (45%)
≥ 15 67 (33.5%)
OCSP classification
TACI 54 (27%)
PACI 102 (51%)
LACI 43 (21.5%)
POCI 1 (0.5%)
Prevalence of risk factors
Hypertension 134 (67%)
Diabetes mellitus 25 (12.5%)
Dyslipidaemia** 154 (77%)
Atrial fibrillation 68 (34%)
Previous stroke 33 (16.5%)
Coronary heart disease 105 (52.5%)
Previous smoker 36 (18%)
Current smoker 40 (20%)
Table 1. Characteristics of the study group 
*Data are numbers (%) unless otherwise stated.
**According to European guidelines on cardiovascular disease prevention in clinical practice
SD – standard deviation, NIHSS – National Institutes of Health Stroke Scale, OCSP –
Oxford Community Stroke Project, TACI – total anterior circulation infarct, PACI – partial
anterior circulation infarct, LACI – lacunar infarct, POCI – posterior circulation infarct
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cal signs in the first CT and type of IS according to
OCSP classification and good clinical outcome at 
3 months according to mRS (0-2), case-fatalities dur-
ing 3 months of onset and SICH by ECASS II defini-
tion are presented in Tables 3-5.
Groups of patients with good and poor outcome, with
and without SICH and groups of patients who died and
who survived did not differ according to the presence of
vascular risk factors, used antiplatelet or anticoagulant
medications at stroke onset and onset-to-needle time.
Good outcome (mRS 0-2) at 3 months was related to
younger age (p = 0.001), male sex (p = 0.02) and low
scores on the NIHSS (< 15 points) (p < 0.0001). Deaths
within 3 months were related to older age (p = 0.027),
female sex (p = 0.004), severity of neurological deficit
measured on the NIHSS (p < 0.0001), baseline systolic
blood pressure (p = 0.003) and presence of radiological
signs of previous stroke in baseline CT (p = 0.002). 
The group of patients with SICH exhibited older
age (p = 0.014) and higher severity of neurological
deficit measured on the NIHSS (p = 0.03), as well as
higher serum glucose on admission (p = 0.044). SICH
was more frequent in women (p = 0.043).
Total anterior circulation infarct (TACI) was relat-
ed to poor outcome (p < 0.0001), death (p < 0.0001)
and SICH (p = 0.006).
Discussion
In the analysed cohort of patients with IS treated
with intravenous thrombolysis, 52.4% of patients were
functionally independent (mRS 0-2) and 16.2% died 
at 90-day follow-up. The proportion of independency
for the NINDS trial was 39% and mortality was 17%;
for pooled randomized control trials those numbers were
50.1% and 17.3%; for the ECASS II trial – 54.3% and
10.6%; for SITS-MOST – 50.4% and 15.5%, respec-
tively [5,18-20]. In the first published report from our
country in a group of 100 cases of patients treated with
rt-PA, 61% had favourable functional outcome with an
mRS of 0-2 and 14% of patients died [13]. Of note, our
patients were older and had higher mean NIHSS scores
than a group of patients from the 2nd Department of
Neurology of the Institute of Psychiatry and Neurolo-
gy [21]. 
Kent et al. [22] using data from 5 major random-
ized clinical trials (n = 2184) with alteplase in the 0-6-
hour window showed that, in addition to rt-PA treat-
ment, seven variables significantly affected prognosis
and/or the treatment effect with rt-PA: age, diabetes,
stroke severity, sex, previous stroke, systolic blood pres-
sure, and time from symptom onset. Catastrophic out-
come was predicted only by age, stroke severity and
serum glucose [22].
We found that male sex was associated with good
outcome, with decreased mortality and with lower inci-
dence of SICH. Our observations are opposite to data
from the pooled analysis by Kent et al. and other stud-
ies [22,23]. Median age in our patients was significantly
lower in the group of patients with good outcome after
3 months from stroke onset, and higher in the group of
patients who died within 3 months and in patients with
SICH. The data from the Austrian Stroke Unit Reg-
istry showed that age emerged as a highly significant
inverse predictor of good functional outcome after
ischaemic stroke independent of stroke severity and oth-
er factors [24]. Older age was one of the independent
predictors of mortality at 3 and 12 months in the Bern
Variable N (%)
Signs of old stroke in baseline CT 73 (36.5%)
Signs of acute stroke in baseline CT
Total 55 (27.5%)
Hyperdense artery sign 18 (9.0%)
Basal ganglia obscuration 35 (17.5%)
Sylvian fissure obscuration 19 (9.5%)
Haemorrhagic transformation in control 35 (17.5%)
CT (2 and 7 days)*
Haemorrhagic infarct type 1 7 (3.5%)
Haemorrhagic infarct type 2 8 (4.0%)
Parenchymal haematoma type 1 8 (4.0%)
Parenchymal haematoma type 2 8 (4.0%)
Parenchymal haematoma remote type 1 4 (2.0%)
Parenchymal haematoma remote type 2 0
Symptomatic intracerebral haemorrhage** 10 (5%)
Cerebral oedema in control CT 
(2 and 7 days)
Total 64 (32%)
Cerebral oedema 1 26 (13%)
Cerebral oedema 2 25 (12.5%)
Cerebral oedema 3 13 (6.5%)
Table 2. Radiological findings in studied patients
*According to the ECASS II criteria
**According to SITS Monitoring Study (SITS-MOST) Final Study Protocol
CT – computed tomography
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Stroke Project [25]. Increasing age was associated with
increased in-hospital mortality also in patients from the
German Stroke Register Study [26].
Our analyses showed no negative impact of vascu-
lar risk factors on the long-term outcome, mortality rate
or the presence of SICH in patients with acute IS treat-
ed with intravenous thrombolysis. We also did not find
any relation between a history of diabetes or baseline
serum glucose and poor outcome and death. The high
baseline glucose level had a statistically significant effect
Patients with good Patients with poor Odds ratio P-value
outcome (mRS 0-2 outcome (mRS 3-6 (95% CI)
at 3 months after at 3 months after
stroke onset) stroke onset)
n = 116 n = 84
Age [years]; mean 66.9 71.5 0.001
Men 62.9% 46.4% 0.51 (0.29-0.90) 0.02
Hypertension 68.1% 65.5% 1.13 (0.62-2.04) 0.70
Diabetes mellitus 13.8% 10.7% 1.33 (0.56-3.18) 0.52
Dyslipidaemia* 75.9% 78.6% 0.86 (0.44-1.68) 0.66
Atrial fibrillation (paroxysmal and persistent) 30.2% 39.3% 0.67 (0.37-1.21) 0.18
Coronary heart disease 56.0% 47.6% 1.40 (0.8-2.46) 0.24
Previous stroke 12.9% 21.4% 0.55 (0.26-1.16) 0.11
Current smoker 24.1% 14.3% 1.91 (0.91-4.02) 0.09
Previous smoker 19.0% 19.1% 0.89 (0.43-1.83) 0.74
Aspirin or other antiplatelet agent at stroke onset 56.0% 60.7% 0.83 (0.47-1.46) 0.51
Oral anticoagulant at stroke onset 14.7% 16.7% 0.86 (0.4-1.86) 0.70
Blood glucose [mmol/L]; mean 6.90 6.96 0.37
Systolic blood pressure > 160 mm Hg 28.5% 48.8% 0.42 (0.23-0.75) 0.003
Diastolic blood pressure > 90 mm Hg 20.7% 32.1% 0.55 (0.29-1.05) 0.07
NIHSS score
≤ 7 30.2% 9.5% 4.11 (1.79-9.41) 0.001
8-14 52.6% 34.5% 2.10 (1.18-3.75) 0.01
> 14 17.2% 56.0% 0.16 (0.09-0.31) < 0.0001
Onset-to-needle time
≤ 90 min 6.9% 9.5% 0.70 (0.25-1.96) 0.50
91-180 min 78.5% 85.7% 0.61 (0.29-1.29) 0.19
181-270 min 12.9% 4.8% 2.97 (0.95-9.3) 0.05
Signs of old stroke in baseline CT 20.7% 53.6% 0.28 (0.15-0.51) < 0.0001
Signs of current stroke in baseline CT 20.7% 36.9% 0.45 (0.24-0.84) 0.01
Clinical stroke syndromes
TACI 12.9% 46.4% 0.17 (0.09-0.34) < 0.0001
PACI 57.8% 38.9% 1.91 (1.08-3.38) 0.025
Table 3. Baseline characteristics of patients treated with alteplase according to the main outcome variables – patients with good versus poor outcome at 3 months
*According to European guidelines on cardiovascular disease prevention in clinical practice
mRS – modified Rankin Scale; CI – confidence interval; CT – computed tomography; NIHSS – National Institutes of Health Stroke Scale; TACI – total anterior circulation infarct; 
PACI – partial anterior circulation infarct
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Patients who survived Patients who died Odds ratio P-value
3 months after within 3 months (95% CI)
stroke onset after stroke onset
n = 169 n = 31
Age [years]; mean 68.3 73.1 0.03
Men 60.4% 32.3% 3.20 (1.42-7.21) 0.004
Hypertension 67.5% 64.5% 0.88 (0.39-1.96) 0.75
Diabetes mellitus 12.4% 13.3% 1.04 (0.33-3.28) 0.83
Dyslipidaemia* 77.5% 74.2% 0.83 (0.35-2.01) 0.69
Atrial fibrillation (paroxysmal and persistent) 32.5% 41.9% 1.50 (0.68-3.27) 0.31
Coronary heart disease 52.1% 54.8% 1.12 (0.52-2.41) 0.77
Previous stroke 15.4% 22.6% 1.60 (0.63-4.11) 0.32
Current smoker 20.7% 16.1% 0.74 (0.26-2.06) 0.56
Previous smoker 19.5% 9.7% 0.44 (0.13-1.54) 0.19
Aspirin or other antiplatelet agent at stroke onset 56.8% 64.5% 1.38 (0.62-3.07) 0.42
Oral anticoagulant at stroke onset 16.0% 12.9% 0.78 (0.25-2.41) 0.87
Blood glucose [mmol/L]; mean 6.86 7.28 0.33
Systolic blood pressure > 160 mm Hg 34.3% 51.6% 2.04 (0.94-4.42) 0.07
Diastolic blood pressure > 90 mm Hg 23.7% 36.7% 1.77 (0.78-4.01) 0.17
NIHSS score
≥ 7 23.7% 9.7% 0.35 (0.10-1.2) 0.08
8-14 50.3% 16.1% 0.19 (0.07-0.52) 0.0004
> 14 26.0% 74.2% 8.17 (3.41-19.6) < 0.0001
Onset-to-needle time
≥ 90 min 7.1% 12.9% 1.94 (0.58-6.46) 0.46
91-180 min 82.7% 77.4% 0.74 (0.29-1.88) 0.53
181-270 min 9.5% 9.7% 1.03 (0.28-3.75) 0.77
Signs of old stroke in baseline CT 32.1% 61.3% 3.37 (1.53-7.44) 0.002
Signs of current stroke in baseline CT 25.0% 41.9% 2.18 (0.99-4.83) 0.05
Clinical stroke syndromes
TACI 20.2% 64.5% 7.22 (3.16-16.5) < 0.0001
PACI 54.8% 32.3% 0.40 (0.18-0.9) 0.023
Table 4. Baseline characteristics of patients treated with alteplase according to the main outcome variables – survivors versus deceased within 3 months after stroke onset
* According to European guidelines on cardiovascular disease prevention in clinical practice
CI – confidence interval; CT – computed tomography; NIHSS – National Institutes of Health Stroke Scale; TACI – total anterior circulation infarct; PACI – partial anterior circulation infarct
on the presence of SICH. In patients with acute IS from
both parts of the NINDS trial, higher admission glu-
cose levels were associated with significantly lower odds
for desirable clinical outcomes and significantly higher
odds for symptomatic intracerebral haemorrhage,
regardless of treatment with alteplase [27]. High blood
glucose was significantly higher in the group of patients
with SICH in the ECASS II trial [18]. Lansberg et al.
[28] conducted a meta-analysis of twelve studies which
met inclusion criteria of a systematic review. Elevated
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serum glucose and history of diabetes were independent
risk factors for thrombolysis-associated SICH in six of
the twelve studies [28].
We found that baseline patient’s status (NIHSS >
14 points) and type of stroke according to the OCSP
classification (TACI) are related to elevated risk of SICH.
Higher NIHSS score was identified as an independent
risk factor of SICH in several previous studies [5,29,
30]. Kablau et al. [31] showed that the development of
haemorrhagic transformation was associated with a more
Patients with SICH Patients without SICH Odds ratio P-value
(according to ECASS II (according to ECASS II (95% CI)
definition) definition)
n = 10 n = 190
Age [years]; mean 77.9 68.6 0.01
Men 20.0% 57.9% 5.5 (1.14-26.6) 0.05
Hypertension 50.0% 67.9% 0.47 (0.13-1.70) 0.41
Diabetes mellitus 33.3% 24.4% 3.27 (0.79-13.6) 0.22
Dyslipidaemia* 80.0% 76.8% 1.21 (0.25-5.89) 0.88
Atrial fibrillation (paroxysmal and persistent) 50.0% 33.2% 2.02 (0.56-7.22) 0.45
Coronary heart disease 40.0% 53.2% 0.59 (0.16-2.15) 0.63
Previous stroke 0 36.7% 0.31
Current smoker 10.0% 20.5% 0.43 (0.05-3.5) 0.69
Previous smoker 10.0% 18.4% 0.49 (0.06-4.01) 0.80
Aspirin or other antiplatelet agent at stroke onset 60.0% 57.9% 1.09 (0.3-3.99) 0.84
Oral anticoagulant at stroke onset 10.0% 15.8% 0.59 (0.07-4.85) 0.96
Blood glucose [mmol/L]; mean 8.51 6.84 0.044
Systolic blood pressure > 160 mm Hg 50.0% 36.3% 1.75 (0.49-6.27) 0.59
Diastolic blood pressure > 90 mm Hg 50.0% 24.2% 3.13 (0.87-11.3) 0.15
NIHSS score
≤ 7 10.0% 22.1% 0.39 (0.05-3.18) 0.61
8-14 20.0% 46.3% 0.29 (0.06-1.4) 0.19
> 14 70.0% 31.6% 5.06 (1.26-20.2) 0.03
Onset-to-needle time
≤ 90 min 10.0% 7.9% 1.30 (0.15-10.9) 0.72
91-180 min 70.0% 82.1% 0.51 (0.16-2.07) 0.59
181-270 min 20.0% 8.9% 2.54 (0.5-12.95) 0.54
Signs of old stroke in baseline CT 60.0% 35.3% 2.75 (0.75-10.1) 0.21
Signs of current stroke in baseline CT 50.0% 26.3% 2.80 (0.78-10.1) 0.21
Clinical stroke syndromes
TACI 70.0% 24.7% 7.10 (1.77-28.3) 0.006
PACI 30.0% 52.1% 0.39 (0.1-1.57) 0.30
Table 5. Baseline characteristics of patients treated with alteplase according to the main outcome variables – patients with symptomatic intracerebral haemorrhage
(SICH) versus patients without SICH
* According to European guidelines on cardiovascular disease prevention in clinical practice
ECASS – European Cooperative Acute Stroke Study; CI – confidence interval; CT – computed tomography; NIHSS – National Institutes of Health Stroke Scale; TACI – total anterior cir-
culation infarct; PACI – partial anterior circulation infarct
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severe neurological deficit on admission and territorial
infarction.
Patients with radiological signs of previous stroke in
baseline CT also had higher risk of death within 
3 months. We did not find a statistically significant cor-
relation between signs of current stroke at baseline CT
and risk of death or SICH. However, it was an inde-
pendent risk factor of SICH in the ECASS II study
[32]. No association of early ischaemic changes with
SICH at 36 hours was detected in the group treated
with rt-PA from the NINDS trial [33].
Conclusions
The indications for intravenous thrombolysis in pa -
tients with IS should be strictly analysed so that the treat-
ment is effective and safe, especially in older patients,
patients with significant severity of neurological symptoms
and patients with old post-stroke lesions in baseline CT. 
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